期刊文献+

盐酸地尔硫联用辛伐他汀治疗不稳定型心绞痛临床观察

Clinical Observation of Herbesser Combined with Simvastatin in Treatment of Unstable Angina Pectoris
下载PDF
导出
摘要 目的:探讨盐酸地尔硫(合贝爽)联用辛伐他汀治疗不稳定型心绞痛(UAP)的临床疗效。方法:将69例不稳定型心绞痛患者随机分为观察组(35例)和对照组(34例),对照组予以常规治疗,观察组在常规治疗的基础上予以合贝爽90mg口服,每日一次,辛伐他汀40mg,每晚睡前口服,疗程均为14d。结果:观察组主要症状和ECG改善情况明显优于对照组,观察组无1例进展为急性心肌梗死(AMI)或死亡,有效率为94.29%,对照组1例进展为AMI,有效率为70.59%,二组比较差异有统计学意义。结论:合贝爽联用辛伐他汀治疗不稳定心绞痛可有效减少心绞痛发作并改善心肌缺血,疗效好且安全可靠。 Objective: To investigate the clinical effect of herbesser combined with simvastatin on unstable angina pectoris. Methods: 69 Patients with unstable angina pectoris were randonmized to study group (n=35) and control group(n=34). The two groups were given tradioned therapy as usual, study group were received additional herbesser (90rag was taken oral per 24h for 14 days) and swovastaffn(40mg was taken oral before sleeping for 14 days). Results: The main symptoms and ECG were alleviated obviously in study group compared with control group. There was no infarction or death in study group.But in control group,a patient developed into acute myocardial infarction.The difference of effective rate between two groups was significant(94.29% Vs 70.59%, P〈0. 01). Conclusions: Herbesser combined with simvastatin can relieve angina pectoris and improve the myocardial ischemic,and it is an effective and safe method.
出处 《中国医药导刊》 2009年第3期437-438,共2页 Chinese Journal of Medicinal Guide
关键词 不稳定型心绞痛 合贝爽 辛伐他汀 Unstablc angina pectoris Herbesser Simvastatin
  • 相关文献

参考文献2

二级参考文献30

  • 1Celermajer DS, Sorensen KE, Gooch VM, et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet, 1992, 340: 1111-1115.
  • 2Anderson TJ,Meredith IT,Yeung AC,et al.The effect of cholesterol-lowering and antioxidant therapy on endothelium- dependent coronary vasomotion.N Engl J Med,1995,332:488-493.
  • 3Jarvisalo MJ,Toikka JO,Vasankari T,et al. HMG CoA reductase inhibitors are related to improved systemic endothelial function in coronary artery disease. Atherosclerosis, 1999,147:237-242.
  • 4Schwartz GG,Olsson AG,Ezekowitz MD,et al.MIRACL Study Investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes :the MIRACL study: a randomized controlled trial. JAMA,2001,285:1711-1718.
  • 5Arntz HR, Agrawal R, Wunderlich W,et al. Beneficial effects of pravastatin(+/-cholestiramine/ niacin)initiated immediately after a coronary event(the randomized Lipid-coronary artery disease[L-CAD]study).Am J Cardiol,2000,86:1293-1298.
  • 6Nissen SE, Tuzcu EM,Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA,2004, 291:1071-1080.
  • 7Cannon CP, Braunwald E, McCabe CH, et al. Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med, 2004, 350:1495-1504.
  • 8Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495-1504.
  • 9LaRosa JC, Grundy SM, Waters DD, et al; Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425-1435.
  • 10Pedersen TR, Faergeman O, Kastelein J J, et al; Incremental Decrease in End Points Through Aggressive Lipid Lowedng (IDEAL) Study Group. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study:a randomized controlled trial. JAMA. 2005;294:2437-2445.

共引文献399

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部